Merus (NASDAQ:MRUS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday. The brokerage presently has a $15.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 15.83% from the stock’s previous close.

According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “

Several other analysts also recently weighed in on MRUS. BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 9th. ValuEngine downgraded Merus from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Merus presently has a consensus rating of “Hold” and an average price target of $21.67.

Shares of NASDAQ MRUS opened at $12.95 on Friday. The stock has a market cap of $294.63 million, a price-to-earnings ratio of -3.02 and a beta of -0.12. Merus has a 1 year low of $11.00 and a 1 year high of $26.74.

Merus (NASDAQ:MRUS) last posted its earnings results on Thursday, December 27th. The biotechnology company reported ($0.55) earnings per share for the quarter. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. The firm had revenue of $7.57 million during the quarter, compared to analysts’ expectations of $4.25 million. As a group, sell-side analysts predict that Merus will post -2.18 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of MRUS. Artal Group S.A. purchased a new stake in shares of Merus in the 4th quarter valued at about $2,886,000. Laurion Capital Management LP purchased a new stake in shares of Merus in the 3rd quarter valued at about $2,104,000. Aquilo Capital Management LLC lifted its holdings in shares of Merus by 3.6% in the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after purchasing an additional 44,799 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after purchasing an additional 30,538 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of Merus in the 3rd quarter valued at about $537,000. 58.76% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Featured Story: Risk Tolerance

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.